GlycoMimetics Inc. is a biotechnology company that specializes in developing therapies based on glycobiology, particularly targeting cancers and inflammatory diseases. Their lead candidate, uproleselan, is a first-in-class E-selectin antagonist currently in pivotal Phase 3 trials for relapsed or refractory acute myeloid leukemia (AML) and in a Phase 2/3 trial for newly diagnosed AML patients. Uproleselan has received Breakthrough Therapy and Fast Track designations from the U.S. FDA, highlighting its potential to significantly improve treatment outcomes for patients with this challenging form of leukemia. The company leverages its proprietary chemistry platform and deep understanding of carbohydrate roles in cell recognition to innovate new therapeutic options.

The foundation of GlycoMimetics' approach lies in glycobiology, which studies the complex interactions between carbohydrates and proteins. By designing glycomimetic compounds that mimic the structure and function of natural carbohydrates, the company aims to enhance therapeutic efficacy and address significant unmet medical needs. Their research focuses on understanding how specific carbohydrate structures influence biological processes, particularly in the context of cancer. This innovative strategy not only aims to improve the effectiveness of existing treatments but also seeks to develop new therapies for various diseases, thereby expanding the potential impact of their research beyond AML.

United States

GlycoMimetics is an oncology-focused biotechnology company. We are dedicated to improving the lives of patients by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates.

Cancer

Genetic Diseases

Hematologic Diseases

Inflammatory disorders

GlycoMimetics Inc

Acute myeloid leukemia

Discovered and developed by GlycoMimetics, uproleselan and GMI-1687 are investigational, first-in-class, targeted inhibitors of E-selectin. Uproleselan is designed to block E-selectin (an adhesion molecule on &nbsp;cells in the bone marrow) from binding with blood cancer cells as a &nbsp;targeted approach to disrupting well-established mechanisms of leukemic &nbsp;cell resistance within the bone marrow microenvironment.
<a href="https://ir.glycomimetics.com/news-releases/news-release-details/compelling-data-mechanism-action-glycomimetics-late-stage">Source</a>

Uproleselan (GMI-1271)

Uproleselan (GMI-1271) +/- Daunorubicin and Cytarabine

Sickle cell disease

Discovered and developed by GlycoMimetics, GMI-1687 is a highly potent E-selectin antagonist that is bioavailable after subcutaneous administration. This second-generation compound has potential application in inflammatory diseases, and the company’s initial clinical development will focus on SCD. E-selectin is believed to play a major role in VOCs, vascular clots and blockages that cause pain crises in people living with the disease. Administration of GMI-1687 by subcutaneous injection, if successfully developed in the clinic, may enable this study drug to be approved as a patient controlled, point-of-care treatment option at time of VOC onset. There currently exists no FDA approved treatment for acute onset of painful and debilitating VOCs.

GMI-1687

Blood cancer

Uproleselan is an investigational first-in-class, E-selectin antagonist. Uproleselan (yoo’ pro le’se lan), currently in a broad Phase 3 development program in acute myeloid leukemia (AML), has received Breakthrough Therapy and Fast Track designations from the U.S. FDA and Breakthrough Therapy designation from the Chinese National Medical Products Administration for the treatment of adult AML patients with relapsed or refractory disease. Uproleselan is designed to block E-selectin binding and stimulation of myeloid cells. E-selectin is expressed on the surface of blood vessels, and its binding to myeloid cells confers a pro-survival effect. Uproleselan is intended to enable a novel approach to disrupting established mechanisms of leukemic cell resistance.

Uproleselan (GMI-1271) +/-fludarabine & cytarabine

Uproleselan (GMI-1271) +/- myeloablative, busulfan-based, pre-transplant conditioning

Breast cancer

<h3 class="font_3">GMI-1359 is designed to simultaneously inhibit both E-selectin and &nbsp;CXCR4. E-selectin and CXCR4 are both adhesion molecules involved in &nbsp;tumor trafficking and metastatic spread. Preclinical studies indicate &nbsp;that targeting both E-selectin and CXCR4 with a single compound could &nbsp;improve efficacy in the treatment of cancers that involve the bone &nbsp;marrow such as acute myeloid leukemia and multiple myeloma or in solid &nbsp;tumors that metastasize to the bone, such as prostate cancer and breast &nbsp;cancer, as well as in osteosarcoma, a rare pediatric tumor.</h3>
<a href="https://ir.glycomimetics.com/news-releases/news-release-details/first-patient-advanced-breast-cancer-receives-first-dose">Source&nbsp;</a>

GMI-1359

Rivipansel, a glycomimetic drug candidate that binds to all three members of the selectin family (E-, P- and L-selectin). Rivipansel is a pan-selectin inhibitor, a molecule that blocks the activity of cell adhesion molecules called <a href="https://www.ncbi.nlm.nih.gov/pubmed/7542213">selectins</a>&nbsp;in the blood vessels. <a href="https://sicklecellanemianews.com/rivipansel-gmi-1070/#:~:text=Rivipansel%20is%20a%20pan%2Dselectin,selectins%20in%20the%20blood%20vessels.">(Source:SickleCellAnemiaNews)</a>

GlycoMimetics Inc

Company Details